Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has informed the Exchange about Investor Presentation for Q1FY27, with robust performance and revenue growth of 36% Y-o-Y, and EBIDTA growth of 87% with margin expansion of ~800 bps on a Y-o-Y basis.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue growing by 36% year-over-year, EBITDA increasing by 87%, and PAT growing by 56%. The company has also expanded its product portfolio, with a strong focus on regulated and emerging markets.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has informed the Exchange regarding the appointment of Ms. Anjali Shah as Assistant Vice President-Finance as Senior Management Personnel (SMP) of the company with effect from July 27, 2026.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on July 27, 2026. The meeting commenced at 01:45 P.M. (IST) and concluded at 02:55 P.M. (IST). The Board approved the appointment and categorization of Ms. Anjali Shah, Assistant Vice President-Finance as Senior Management Personnel of the Company with effect from July 27, 2026. The unaudited consolidated and standalone financial results for the quarter ended June 30, 2026, together with the Limited Review Report thereon, were also approved.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has announced its unaudited consolidated and standalone financial results for the quarter ended June 30, 2026, along with the limited review report of its statutory auditors. The company has also announced the appointment of Ms. Anjali Shah as Senior Management Personnel with effect from July 27, 2026.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has scheduled an earnings conference call for Q1FY27 on July 27, 2026, following the announcement of unaudited consolidated and standalone financial results for the quarter ended June 30, 2026.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has submitted the Reconciliation of Share Capital Audit Report for the quarter ended June 30, 2026, as per SEBI (Depositories and Participants) Regulations, 2018.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026, confirming the acceptance or rejection of dematerialized securities and listing of securities on stock exchanges.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has informed the Exchange regarding the completion of dispatch of Notice of Postal Ballot, intimation of e-voting and other related information.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has informed the Exchange regarding a Postal Ballot Notice for seeking approval of shareholders on several items of Special Business, including related party transactions and loan/guarantee enhancements.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has informed the Exchange about a scheduled meeting with analysts and institutional investors at its plant in Chhatral, Gujarat, and corporate office in Ahmedabad, Gujarat, on July 7, 2026.

Senores Pharmaceuticals Limited

The board of directors of Senores Pharmaceuticals Limited has approved a variation in the utilization of unutilized IPO proceeds to the extent of ₹ 1000.16 million, subject to shareholder approval through postal ballot.

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the announcement of unaudited financial results for the quarter ending June 30, 2026.